In a week when markets were supposed to be focused on holiday retail and year-end dot plots, the real action was happening in places that do not show up on Black Friday traffic Chinese export control offices and a Western Australian gallium…
If 2024 crowned weight-loss drugs the belle of the healthcare ball, 2025 belongs to the bispecific antibody. What began as a niche in immuno-oncology has evolved into biotech’s most competitive—and potentially lucrative—battleground, drawing fresh capital, dealmaking, and analyst optimism that borders on…
US rates have been drifting higher over the past week mainly because stronger economic data and the run‑up to the Fed’s December meeting are pushing investors to price in fewer or later rate cuts, which lifts Treasury yields and market borrowing costs.…
Wall Street spent Tuesday marking time and watching the clock, as markets drifted in tight formation ahead of Wednesday’s Fed decision, with just enough sector rotation and deal drama to keep traders from checking out entirely.
Indexes and macro tone
The major…
Microsoft’s latest investment wave is rolling eastward — and this time, it’s not the Nordics reaping the cloud bounty but India, now the company’s fastest-growing market outside the United States. The tech giant is earmarking $17.5 billion to expand data centers, AI…
Traders on Wall Street like to pretend they are focused on the “decision,” but this week the 25 basis points are just the opening act; the real drama arrives in the footnotes, charts, and carefully hedged adverbs of the Fed’s 2026 guidance.…
For much of the post-pandemic era, the American job market was powered by swagger. Workers hopped jobs, demanded signing bonuses, and treated two-week notices like optional courtesies. But as autumn set in, the swagger dimmed.
Layoffs rose to 1.85 million in October,…
Donald Trump’s decision to let Nvidia resume selling advanced chips to China turns export controls into a new form of dealmaking, one that blends national security with revenue sharing. It also tests how far he is willing to go in using America’s…
Wall Street opened the week in a cautious mood Monday, with the major averages edging lower as investors stared down a data‑thin calendar and a Fed meeting that promises more intrigue than drama. The Dow Jones Industrial Average slipped around six‑tenths of…
GeoVax’s (NASDAQ: GOVX) latest cameo in JCO Oncology Advances reads like the opening argument for an oncology re-rate, with its gene-directed cancer therapy Gedeptin now backed by human data that suggest the platform is more than clever lab work. For a company many investors…